The Network of Pluripotency, Epithelial-mesenchymal Transition, and Prognosis of Breast Cancer

Overview

Journal Breast Cancer (Dove Med Press)

Publisher Dove Medical Press

Date 2015 Sep 18

PMID 26379447

Citations 21

Authors

Ioannis A Voutsadakis

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the leading female cancer in terms of prevalence. Progress in molecular biology has brought forward a better understanding of its pathogenesis that has led to better prognostication and treatment. Subtypes of breast cancer have been identified at the genomic level and guide therapeutic decisions based on their biology and the expected benefit from various interventions. Despite this progress, a significant percentage of patients die from their disease and further improvements are needed. The cancer stem cell theory and the epithelial-mesenchymal transition are two comparatively novel concepts that have been introduced in the area of cancer research and are actively investigated. Both processes have their physiologic roots in normal development and common mediators have begun to surface. This review discusses the associations of these networks as a prognostic framework in breast cancer.

Citing Articles

Molecular Characteristics and Therapeutic Vulnerabilities of Claudin-low Breast Cancers Derived from Cell Line Models.

Voutsadakis I Cancer Genomics Proteomics. 2023; 20(6):539-555.

PMID: 37889067 PMC: 10614063. DOI: 10.21873/cgp.20404.

PIK3CD correlates with prognosis, epithelial-mesenchymal transition and tumor immune infiltration in breast carcinoma.

He W, Zhang H, Cheng H, Wen J, Li D Discov Oncol. 2023; 14(1):187.

PMID: 37861728 PMC: 10589178. DOI: 10.1007/s12672-023-00805-0.

EMT Features in Claudin-Low versus Claudin-Non-Suppressed Breast Cancers and the Role of Epigenetic Modifications.

Voutsadakis I Curr Issues Mol Biol. 2023; 45(7):6040-6054.

PMID: 37504297 PMC: 10378159. DOI: 10.3390/cimb45070381.

Comparison of Clinical Subtypes of Breast Cancer within the Claudin-Low Molecular Cluster Reveals Distinct Phenotypes.

Voutsadakis I Cancers (Basel). 2023; 15(10).

PMID: 37345027 PMC: 10216296. DOI: 10.3390/cancers15102689.

Reprogramming by Cytosolic Extract of Human Embryonic Stem Cells to Improve Dopaminergic Differentiation Potential of Human Adipose Tissue-derived Stem Cells.

Mobasseri S, Javeri A, Taha M Basic Clin Neurosci. 2022; 13(2):247-255.

PMID: 36425950 PMC: 9682313. DOI: 10.32598/bcn.12.6.2069.1.

References

Markiewicz A, Ahrends T, Welnicka-Jaskiewicz M, Seroczynska B, Skokowski J, Jaskiewicz J . Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer. J Transl Med. 2012; 10:226. PMC: 3524044. DOI: 10.1186/1479-5876-10-226. View

Riaz M, Sieuwerts A, Look M, Timmermans M, Smid M, Foekens J . High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes. Breast Cancer Res. 2012; 14(5):R123. PMC: 4053101. DOI: 10.1186/bcr3317. View

Korpal M, Ell B, Buffa F, Ibrahim T, Blanco M, Celia-Terrassa T . Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med. 2011; 17(9):1101-8. PMC: 3169707. DOI: 10.1038/nm.2401. View

Lin Y, Yang Y, Li W, Chen Q, Li J, Pan X . Reciprocal regulation of Akt and Oct4 promotes the self-renewal and survival of embryonal carcinoma cells. Mol Cell. 2012; 48(4):627-40. PMC: 3601782. DOI: 10.1016/j.molcel.2012.08.030. View

Koopmansch B, Berx G, Foidart J, Gilles C, Winkler R . Interplay between KLF4 and ZEB2/SIP1 in the regulation of E-cadherin expression. Biochem Biophys Res Commun. 2013; 431(4):652-7. DOI: 10.1016/j.bbrc.2013.01.070. View

Schlotter C, Vogt U, Bosse U, Mersch B, Wassmann K . C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res. 2003; 5(2):R30-6. PMC: 154146. DOI: 10.1186/bcr568. View

Simoes B, Piva M, Iriondo O, Comaills V, Lopez-Ruiz J, Zabalza I . Effects of estrogen on the proportion of stem cells in the breast. Breast Cancer Res Treat. 2010; 129(1):23-35. DOI: 10.1007/s10549-010-1169-4. View

Anokye-Danso F, Trivedi C, Juhr D, Gupta M, Cui Z, Tian Y . Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell. 2011; 8(4):376-88. PMC: 3090650. DOI: 10.1016/j.stem.2011.03.001. View

Boyer L, Lee T, Cole M, Johnstone S, Levine S, Zucker J . Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 2005; 122(6):947-56. PMC: 3006442. DOI: 10.1016/j.cell.2005.08.020. View

10.

Hassiotou F, Hepworth A, Beltran A, Mathews M, Stuebe A, Hartmann P . Expression of the Pluripotency Transcription Factor OCT4 in the Normal and Aberrant Mammary Gland. Front Oncol. 2013; 3:79. PMC: 3622876. DOI: 10.3389/fonc.2013.00079. View

11.

Kehler J, Tolkunova E, Koschorz B, Pesce M, Gentile L, Boiani M . Oct4 is required for primordial germ cell survival. EMBO Rep. 2004; 5(11):1078-83. PMC: 1299174. DOI: 10.1038/sj.embor.7400279. View

12.

Vesuna F, Lisok A, Kimble B, Domek J, Kato Y, van der Groep P . Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α. Oncogene. 2011; 31(27):3223-34. PMC: 3276743. DOI: 10.1038/onc.2011.483. View

13.

Judson R, Babiarz J, Venere M, Blelloch R . Embryonic stem cell-specific microRNAs promote induced pluripotency. Nat Biotechnol. 2009; 27(5):459-61. PMC: 2743930. DOI: 10.1038/nbt.1535. View

14.

Johnson S, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A . RAS is regulated by the let-7 microRNA family. Cell. 2005; 120(5):635-47. DOI: 10.1016/j.cell.2005.01.014. View

15.

Fang X, Cai Y, Liu J, Wang Z, Wu Q, Zhang Z . Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal. Oncogene. 2011; 30(47):4707-20. DOI: 10.1038/onc.2011.181. View

16.

ODonnell K, Wentzel E, Zeller K, Dang C, Mendell J . c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005; 435(7043):839-43. DOI: 10.1038/nature03677. View

17.

Knoepfler P . Why myc? An unexpected ingredient in the stem cell cocktail. Cell Stem Cell. 2008; 2(1):18-21. DOI: 10.1016/j.stem.2007.12.004. View

18.

Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik J, Lee H . Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010; 468(7320):98-102. PMC: 3084017. DOI: 10.1038/nature09387. View

19.

Foubert E, De Craene B, Berx G . Key signalling nodes in mammary gland development and cancer. The Snail1-Twist1 conspiracy in malignant breast cancer progression. Breast Cancer Res. 2010; 12(3):206. PMC: 2917026. DOI: 10.1186/bcr2585. View

20.

Hermeking H . MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer. 2012; 12(9):613-26. DOI: 10.1038/nrc3318. View